vorasidenib
servier
['vorasidenib']
 pfs was significantly improved in the vorasidenib group as compared with the placebo group (median pfs, 27.7 months vs. 11.1 months; hazard ratio for disease progression or death, 0.39; 95% confidence interval [ci], 0.27 to 0.56; p&lt;0.001). #asco23 
Neuro-oncologist practicing at Smilow Cancer Hospital and the Yale Comprehensive Cancer Center, dedicated to Hope and the pursuit of the Cure. Tweets are my own